Showing results (341-350 of 6,286) with videos related to
Sort By:
Pageof 629
Diabetes, Obesity & Metabolism|March 9, 2018
Ethnic differences in insulin secretory function between black African and white European men with early type 2 diabetesCynthia Mohandas, Riccardo Bonadonna, Fariba Shojee-Moradie, et al.Diabetes, Obesity & Metabolism|July 7, 2016
Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trialT S Bailey, R Takács, F J Tinahones, et al.Diabetes, Obesity & Metabolism|August 4, 2017
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational studyFrederik Persson, Thomas Nyström, Marit E Jørgensen, et al.Diabetes, Obesity & Metabolism|February 17, 2018
The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetesMartin Haluzík, Greg Fulcher, Thomas R Pieber, et al.Diabetes, Obesity & Metabolism|January 24, 2023
Therapeutic inertia related to the injectable glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes in UK primary careLill-Brith von Arx, Jonathan Rachman, Joanne Webb, et al.Diabetes, Obesity & Metabolism|January 26, 2023
Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmesVanita R Aroda, Umut Erhan, Peter Jelnes, et al.Diabetes, Obesity & Metabolism|November 13, 2001
Effects of granulocyte-colony stimulating factor in the treatment of diabetic foot infectionA Yönem, B Cakir, S Güler, et al.Diabetes, Obesity & Metabolism|November 13, 2001
Overexpression of the A1 adenosine receptor in adipose tissue protects mice from obesity-related insulin resistanceQ Dong, H N Ginsberg, B F ErlangerDiabetes, Obesity & Metabolism|April 12, 2001
Differential effects of short and long duration insulinotropic agents on meal-related glucose excursionsC J de Souza, P Russo, R Lozito, et al.Diabetes, Obesity & Metabolism|February 28, 2001
Insulin resistance: the fundamental trigger of type 2 diabetesL C GroopPageof 629